REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that its fourth quarter and full year 2022 financial results will be released after market close on Monday, March 6, 2023. Starting at 5:00 pm ET on March 6, 2023, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
A replay of the webcast will be available on http://investors.coherus.com following the conclusion of the live conference call.
Conference Call Information
When: Monday, March 6th, 2023, starting at 5:00 p.m. Eastern Time
To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register.vevent.com/register/BI8a3cc318d81c4ebaa9d8f6e635f9731c
Webcast: https://edge.media-server.com/mmc/p/jcpis3ko
The press release with the fourth quarter and full year 2022 financial results and related materials will be available at https://investors.coherus.com prior to the start of the conference call.
A live and archived webcast will be available on the “Investors” section of the Coherus website at http://investors.coherus.com.
Please dial-in 15 minutes early to ensure a timely connection to the call.
Coherus Contact Information:
Marek Ciszewski, SVP Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.88 |
| Daily Change: | -0.01 -1.65 |
| Daily Volume: | 607,328 |
| Market Cap: | US$102.130M |
May 12, 2025 March 10, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
